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SUMMARY 
Antiparasitic pharmaceuticals are important groups of pharmaceuticals in veterinary medicine 
and are used in large quantities. Antiparasitic pharmaceuticals and their metabolites enter the 
environment via excretion in urine and/or faeces from treated animals and by run off to surface 
water these compounds reach aquatic environments and thereby present a risk for aquatic 
organisms. The goal of this master thesis is to investigate if veterinary antiparasitic 
pharmaceuticals have any effects on the behaviour of zebrafish larvae. In addition, adding of a 
behavioural assay could increase sensitivity in the fish embryo toxicity test. There are some 
studies of toxicity of veterinary pharmaceuticals in aquatic animals, but they focus mainly on 
general toxic effects. Several of the antiparasitic pharmaceuticals has a neurotoxic mechanism 
of action, and may therefore affect behaviour of zebrafish larvae, which in turn can affect its 
responses to stimuli and the survival of the larvae in its natural environment. 
In this study zebrafish larvae were exposed, from day 0 until day 6, to three different 
antiparasitic pharmaceuticals: doramectin, flumethrin and toltrazuril. An additional study was 
performed with doramectin, in order to study the effects of short time exposure. In the short 
term study the embryos were exposed to doramectin at day 6 for 1 h before behaviour recording. 
In the long time exposure experiments a behavioural assay was performed at day 6 using a 
video recording device (Viewpoint Zebrabox®) that recorded the swim activity of the larvae. 
Directly after the behavioural assay the larvae were assessed in stereo microscope for 
abnormalities and abnormal body posture. Only data from individuals that were considered as 
normal according to the macroscopic examination were included in the data set and used in the 
statistical analyses. Because of the large amount of data that were received from the recording 
device, four responses were chosen for statistical analysis: mean activity during the first period 
of darkness, mean activity during the first period of darkness, increase in activity during the 
first 10 seconds at the first period of darkness and difference between mean activity during the 
first and the last period of darkness.  
Significant results were found for doramectin and flumethrin. The activity in the first five 
minutes dark period and the first five minutes light period were both significantly reduced in 
larvae exposed to the high concentration (0.58 mg/L) of doramectin compared with the control. 
Larvae exposed to the high concentration (0.11 mg/L) of flumethrin had a significant higher 
reduction in activity from the first to the last dark period as compared with the reduction in 
control larvae. The conclusion is that it is possible to detect altered behavioural response, in 
individuals that could not be classified as affected based on visual features. This finding 
supports that behavioural assays are potential tools to increase the sensitivity in toxicological 
studies in zebrafish.  
  
SAMMANFATTNING 
Antiparasitära läkemedel är en läkemedelsklass som används i stor mängd inom 
veterinärmedicinen och som sannolikt kommer ut i miljön via urin och faeces från behandlade 
djur. Via bland annat avrinning från åkrar där gödsel och urin från djuren spridits så kan dessa 
substanser, och dess eventuella metaboliter, nå vattendrag och därmed utgöra en risk för 
vattenlevande organismer. Syftet med studien är att studera hur zebrafiskyngels beteende 
påverkas av tre olika läkemedels substanser ur denna läkemedelsklass. Ett annat syfte var även 
att undersöka om beteendestudier kan öka känsligheten i toxiska tester.  Det finns en del data 
gällande generella toxiska effekter av veterinärmedicinska läkemedel på vattenlevande 
organismer, däremot få studier om hur de påverkar beteendet hos dessa djur. Flera antiparasitära 
läkemedel är neurotoxiska och antas därigenom kunna påverka beteende, vilket i sin tur antas 
kunna påverka dessa djurs respons på olika stimuli och därigenom deras överlevnad i naturen.  
I denna studie exponerades zebrafiskembryon från dag 0 till dag 6 för tre olika 
läkemedelssubstanser, doramektin, flumetrin och toltrazuril enligt en standardiserad metod. Det 
gjordes även ett försök med korttidsexponering där embryona exponerades för doramektin dag 
6, under en timme innan avläsning. I långtidsexponeringarna utfördes en beteendeanalys dag 6 
avseende påverkan på aktivitetsnivån (simaktiviteten) med hjälp av ett videoanalyssystem 
(Viewpoint Zebrabox®). Direkt efter videoanalysen gjordes en visuell bedömning av embryona 
avseende fysiologiska och morfologiska avvikelser samt avvikelser i kroppspositionering. 
Endast data från embryon som inte uppvisade några förändringar inkluderades i de data som 
analyserades statistiskt. Ur den stora mängd data som erhölls valdes fyra responser ut för 
statistisk analys: aktivitet under de 10 första sekunderna under första mörkerperioden, 
medelaktivitet under första mörkerperioden, medelaktivitet under första ljusperioden, samt 
skillnad i medelaktivitet mellan första och sista mörkerperioden.  
Signifikant resultat erhölls för högsta koncentrationen av flumetrin och doramektin. Flumetrin 
i koncentrationen 0,11 mg/L gav en signifikant sänkning i medelaktivitet mellan första och sista 
mörkerperioden hos de exponerade ynglen jämfört med kontrollen. Yngel som exponerats för 
doramektin i koncentrationen 0,58 mg/L hade lägre aktivitet både under första mörkerperioden 
och under första ljusperioden. Det var således möjligt att med metoden detektera 
beteendeförändringar hos yngel som vid en visuell bedömning klassificerades som normala och 
detta talar för att beteendeanalys kan vara användbart för att öka känsligheten i toxikologiska 
studier på zebrafisk. 
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INTRODUCTION 
Antiparasitic drugs are important groups of pharmaceuticals that are widely used for veterinary 
purposes. They are administrated to animals to treat or prevent parasitic infections and can be 
administrated topically, orally or injected intramuscular/subcutanous. The major route of entry 
into the environment is probably via excretion to urine and/or faeces. The antiparasitic 
compounds and/or their metabolites are then released in the in the environment either directly 
from grazing livestock or by the disposal of manure and slurry to agriculture land. By run off 
to surface water the antiparasitic compounds can reach aquatic environments and thereby 
present a risk for aquatic organisms.  
There are some studies (Wollenberger et al., 2000; Oh et al., 2006; Carlsson et al., 2013) where 
the toxicity of veterinary pharmaceuticals in aquatic animals have been examined. These studies 
focusing mainly on general toxic effects, not on behavioural effects. Carlsson et al., (2013) 
investigated the toxicity of 15 different veterinary pharmaceuticals. Several substances in that 
study were antiparasitic pharmaceuticals, some of which are known to have neurotoxic 
mechanisms of action in their target organisms. It is possible that drugs acting on the nerve 
system may lead to altered behaviour in fishes and there are some studies done (Beauvais et al., 
2000; Chen et al., 2012; Domingues et al., 2016), but there are currently few studies done that 
focus specifically on the effects veterinary pharmaceuticals. An altered behaviour, either caused 
by direct neurotoxicity or due to developmental abnormities may have an impact of the survival 
of the animal (Tierney, 2011). Behaviour are responses to cues, either from the animal itself or 
from its environment, with the intention to increase the animal’s fitness. Detecting a deviant or 
impaired behaviour is therefore an interesting and relevant endpoint in toxicity tests.  
The goal of this master thesis is to investigate if three different veterinary antiparasitic 
compounds have any neurotoxic effects on zebrafish larvae (Danio rerio). In addition, if a 
behavioural assay could increase sensitivity in fish embryo toxicity tests.   
LITERATURE REVIEW 
Pharmaceuticals in the environment  
Low levels of veterinary pharmaceuticals have been detected worldwide in soils, surface water 
and groundwater (Boxall et al., 2003). The consequences of this has been widely studied for 
some groups of pharmaceuticals such as anthelmintics and some antibacterial compounds, but 
remains unclear for many other substances.  
Veterinary drugs can enter the environment via several different pathways (Halling-Sørensen 
et al., 1998; Boxall et al., 2003). They can be released as emissions from pharmaceutical 
factories during the manufacture, be released from pharmaceuticals and their containers that are 
disposed after usage or be released from the animal during the treatment process. How the drug 
is emitted during the treatment process will depend on way of administration and on the 
methods of animal husbandry. The most important routes of entry into the environment are 
likely the discharge of aquaculture products, the wash-off of topical treatments and the 
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excretion of substances in urine and faeces of livestock (Boxall et al., 2003). Contributions 
from the manufacturing process are likely low in the US and EU due to strict regulatory controls 
of manufacturing and formulation of pharmaceuticals. Another possibility is that veterinary 
drugs enter the environment as aerosols or dusts, but the significance of these releases is 
unknown. Also the impacts of emissions from treating pets and disposing of unused or expired 
products cannot be established but researchers consider emissions via these routes less relevant 
than emissions from treatment of aquaculture and livestock animals.  
When released into the environment veterinary compounds will be distributed to air, water, soil, 
or sediment (Boxall et al., 2003). The distribution pattern will be influenced by the 
physicochemical properties of the substance, the extent of degradation, its propensity to 
partition to soil and sediment and the characteristics of the receiving environment. Chemical 
properties such as water solubility, pH of the matrix, volatility, and sorption potential will 
influence its behaviour. Also the level of degradation will play a major role for how much of 
the pharmaceutical that will reach the environment and how persistent it will be. Rate of 
degradation of pharmaceuticals can vary significantly across chemicals. The environment, in 
which the pharmaceutical ends up, also effects the rate of degradation due to environmental 
conditions such as temperature, soil type, and pH. The same component can have different 
degradation rates in manure, slurry, soil and water. Even smaller differences, such as various 
manure types can have a significant effect. The degradation process generally reduces the 
potency of the pharmaceutical but there also exist degradation products that have similar 
toxicity to their parent compound (Boxall et al., 2003).  
Antiparasitic pharmaceuticals 
According to the 2015 annual report of veterinary pharmaceutical sales a total of 20353 kg 
(active substance) of antiparasitic pharmaceuticals were sold during 2015 (Jordbruksverket, 
2015). This was an increase from the previous year by 4218 kg. A big part of the sales consisted 
of sulfonamides and triazins sold as feed additives for production animals i.e. poultry. The 
following antiparasitic substances were on the list as the most sold antiparasitics in Sweden 
during 2015: sulphonamides, triazins, quinolones, benzimidazoles, tetrahydropyrimidines, 
pyretrins and pyretroids, avermectines and milbemycines.  
Sulphonamides are used as a food additive to prevent coccidiosis in poultry (Siddiki et al., 
2008). It is a competitive antagonist of para-aminobenzoic acid (PABA), which is a precursor 
of folic acid in protozoa and bacteria. Folic acid is a coenzyme necessary for the synthesis of 
nucleic acid. Triazins are used to treat coccidiosis in several species. It affects the perinuclear 
space, mitochondria, and the endoplasmatic reticulum of the parasites and leads to an reduce of 
enzymes in the respiratory chain such as succinate-cytochrome C reductase, NADH oxidase 
and succinate oxidase (Harder & Haberkorn, 1989). Quinolones such as praziquantel, are used 
to treat tapeworm infections. They increase calcium permeability of parasite muscle and/or 
tegumental membranes (Martin, 1997). The increased Ca+ influx across the tegument cause a 
rapid muscle contraction of the parasite. Benzimidazols are also used as anthelmintics for 
treatment of nematode infections (Lacey, 1990). They bind to microtubulin, a component of the 
cytoskeleton of eukaryotic cells, and thereby inhibit the polymerisation. 
Tetrahydropyrimidines, such as pyrantel, another anthelmintic for treatment of nematode 
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infections, acts by disrupting neuromuscular transmission in nematodes (Rayes et al., 2001). It 
causes depolarization of the muscle membranes in nematodes by acting as an agonist of 
nicotinic receptors (AChRs). Pyrethrins and pyrethroids are used to control ectoparasites in 
animals (Valentine, 1990). They act on voltage-dependent sodium channels in nerves by 
slowing down the closing of the sodium activation gate which result in neural dysfunction. 
Some pyrethroids has a second mechanism of action, they disrupting the nerve signals by 
inhibiting the peripheral gamma amino butyric acid (GABA) receptors, which are unique to 
arthropod muscles. Avermectines and milbemycines are anthelmintics, belonging to 
macrocyclic lactones, belong to endectocides and are used for treatment of both nematode 
infections and ectoparasities. Avermectines and milbemycines increase the muscle Cl- 
permeability by opening  glutamate-gated Cl--channels and thereby cause paralysis (Martin, 
1997). They also act at lower concentrations by potentiating the effect of glutamate.  
Few of the anthelmintics and endectocides are completely metabolised to inactive molecules 
within the host (McKellar, 1997). This means that antiparasitic pharmaceuticals with biological 
activity are normally excreted in the urine or faeces of the treated animals and that way may 
present a risk for non-target organisms. The amount of an antiparasitic compound that will enter 
the environment depends on the husbandry systems and stocking densities of the treated 
animals. The ecotoxicological effects may also be diminished if non-treated animals within the 
herd contribute with uncontaminated faeces. For the individual treated animal, the contribution 
will depend on amount of the substance, method of delivery (faeces, urine, wash off), the extent 
of metabolism and level of excretion of biologically active molecules. 
After being excreted some antiparasitic compounds can cause harm to non-target organisms 
(McKellar, 1997). It has been proven that members of the avermectin/milbemycin group effects 
on non-target organisms that are utilising the faeces of the treated animals. Ivermectin residues 
in the dung has reduced, or even prevented, breakdown of pats by insect activity (Strong et al., 
1996). Antiparasitic pharmaceuticals, such as benzoylphenylurea insecticides and pyrethroids, 
such as pyrethrins and pyrethroids, are also used in aquaculture to treat parasitic infections in 
fishes kept for food production. In a Norwegian study (Langford et al., 2014) antiparasitic 
compounds were detected in wild shrimps at levels at which chronic effects are seen in 
experimental studies on this species. This suggest that antiparasitic pharmaceuticals from 
aquaculture is a potential risk to these animals.  
Toxicity of antiparasitic pharmaceuticals to water living or organisms have been tested in 
several studies. In a study by Yoshimura & Endoh, (2005) acute toxicity of five antiparasitic 
pharmaceuticals used in the veterinary field were tested. The five pharmaceuticals that were 
included in the study were amprolium hydrochloride, bithionol, levamisole hydrochloride, 
pyrimethamine and trichlorfon. They were tested for acute toxicity on three aquatic species: 
Oryzias latipes, Daphnia magna, and Brachionus calyciflorus. The least toxic substance to 
these organisms were amprolium hydrochloride, were the LC50 concentration ranged between 
227 mg L-1 for the most sensible species to >600 mg L-1 for the most tolerant one. Bithionol 
was the most toxic substance for O. latipes (LC50 of 0.24 mg L-1). D. magna was the most 
susceptible species to trichlorfon (EC50 0.00026 mg L-1) while B. calyciflorus was the most 
susceptible species to bithionol (EC50 0.063 mg L-1). Carlsson et al. (2013) tested the toxicity 
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of 15 veterinary pharmaceuticals by using the Fish Embryo Toxicity (FET) test on zebrafish. 
Ten of the tested substances were antiparasitic compounds and they were able to determine 
EC50-values for eight of them. Four benzimidazoles were tested: albendazole (EC50 of 0.042 
mg/L), febantel (EC50 of 0.34 mg/L), fenbendazole (EC50 of 0.024 mg/L) and oxfendazole 
(EC50 of 6.8 mg/L). Two avermectines, doramectin and ivermectin, were tested and were found 
to have EC50 values of 0.58 mg/L respectively 0.44 mg/L. The two remaining substances were 
flumethrin (a pyrethroid) with an EC50 of 0.11 mg/L and toltrazuril (a triazin) with an EC50 of 
1.1 mg/L.  
Fish Embryo Toxicity (FET) test  
The zebrafish embryo toxicity test is a popular model used to study toxicity. The advantages 
are many; zebrafishes are easy to keep and handle, they are relatively inexpensive, the produce 
a large number of progeny and they have a rapid embryo development. Another advantage is 
that they are egg laying and their eggs are transparent which makes it easy to follow the 
developmental process (Goldsmith, 2004; Lieschke & Currie, 2007). The embryos can be kept 
in microtiter plates in a very small volume of water and because of their yolk sac they do not 
have to be fed. Only a small amount of the toxic compound, that are going to be tested, are 
needed. The embryos develop organs that are similar to their mammalian counterparts at an 
anatomical, physiological and molecular level.  
The principle for the test is that newly fertilized embryos are exposed for the substance for a 
total of 96 h (OECD, 2013) . The embryos are then observed every 24 h for four lethal 
indicators: coagulation of fertilized eggs, lack of somite formation, lack of detachment of the 
tail bud from the yolk sac, lack of heartbeat. A somite is a division of the body of an animal or 
embryo and an indication of that they have been formed is that the embryo shows spontaneous 
movements (typically side-to-side contractions). Hatching rates of the embryos are recorded 
from 48 h and onward. The test is terminated after 96h. Based on the recordings of those four 
lethal indicators, acute toxicity is determined and the LC50 is calculated. Experiments in fish 
embryos do not need approval from an Ethical Committee on Animal Experiments, if the 
experiment is ended before the larvae reaches the age when they start eating (2 cap. 5 § Statens 
jordbruksverks föreskrifter och allmänna råd [SJVFS 2012:26] om försöksdjur, L 150). 
Behaviour of zebrafish larvae 
Zebrafish larvae has also several advantages when it comes to behavioural studies. Newly-
hatched zebrafish larvae have a rich behavioural repertoire (Budick & O’Malley, 2000; Burgess 
& Granato, 2007). At the same time they have less diversity of their locomotor repertoire 
compared to vertebrates with more complex behaviour. This, together with their small size, 
makes it easier to assess behaviour using objective quantification methods. Fish larvae has a 
nervous system of limited complexity but at the same share many features with the mammalian 
neuroanatomy.  
Several locomotor behaviours has been described in zebrafish larvae such as optomotor 
response, prey tracking, phototaxis and escape response (Burgess & Granato, 2007). Optomotor 
response is a behaviour in which the larvae turns and swim in the direction of a perceived 
motion, after being presented with a whole-field moving stimulus, (Portugues & Engert, 2009). 
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This behaviour can at earliest be detected 5 days post fertilization shall be present in the larvae 
at day 7. The behaviour persists throughout adulthood. Prey tracking is a complex behaviour 
consisting of several parts. Firstly, the larvae have to spot and identify the prey. Then it starts 
to track the prey and swims and turns slowly. This part of the prey tracking behaviour demands 
very fine motor control. Finally, the larvae starts the swim to capture the prey. The larval escape 
or visual startle response are fully developed in zebrafish at 79 hours post fertilization (Easter 
& Nicola, 1996). The locomotor activity of zebrafish larvae are affected by exposure to dark or 
light conditions (Padilla et al., 2011). When zebrafish larvae (6d hpf) were exposed to light 
they showed an increase in locomotor activity when the light was switched off and they were 
left in completely darkness. Also if the light was switched to a lower level, but not to complete 
darkness, they showed an increase in activity. Padilla et al. (2011) tested switching between 
different light levels. They found that the larger difference in light level between the lighter and 
the darker period was, the more locomotor activity in the larvae. This implies that the changes 
in activity is caused by the contrast between the different light levels and not by the simple 
change from light to darkness. In the present study we will use response to dark and light as a 
tool to access altered behavioural response in larvae exposed to three different antiparasitic 
pharmaceuticals.  
MATERIAL AND METHODS 
Pharmaceuticals 
Three antiparasitic compunds were tested in the present study: doramectin, flumetrine and 
toltrazuril (supplier: Sigma–Aldrich). The selection of substances was based on a previous 
study by (Carlsson et al., 2013) in which 15 veterinary pharmaceuticals were tested for toxicity 
in zebrafish embryos. Doramectin and fluethrin were chosen because of their potential 
neurotoxic effects which make them highly interesting in a behavioural assay. Toltrazuril was 
included because it, in high concentrations, reduced early spontaneous movements in the 
zebrafish embryos. The concentrations used in the present study were based on the EC50 values 
in (Carlsson et al., 2013) with the EC50 representing the highest concentration. The low 
concentration was set to 10 times less than EC50 and the medium concentration to be in the 
middle of the high and the low concentration based on a logarithmic scale. Stock solutions were 
prepared by dissolving the three substances in dimethyl sulfoxide (DMSO). The medium used 
for the larvae were carbon filtered and aerated tap-water with a temperature of 26°C and a pH 
of 8.2. 
Rearing of parental fish 
Adult zebrafish were kept in two tanks with a flow-through system of carbon filtered tap-water. 
The photoperiod was 12 h darkness and 12 h light. Water temperature was kept at 26 °C and 
the fishes were feed twice a day with commercial flakes (SERA Vipan).  
Egg collection 
In the afternoon, the day before egg laying, adult zebrafish were moved from their original 
tanks and placed in cages in four 20L tanks with 6-7 females and 5-6males in each. The cages 
were then moved to new tanks, same number and size, in the morning to ensure that the eggs 
collected were freshly laid. The fishes were allowed to spawn for 1 h from onset of light and 
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the eggs were then collected and transferred to a petri dish. Before starting the test procedure, 
the eggs were checked to have developed at least to the four cell stage to ensure fertilization 
and acceptable egg quality. 
Exposure design 
The exposure design is visualized in table 1. In the present study 0.1 % DMSO were used in 
the final solutions. OECD (2013) recommend that if a solvent is needed for the solution 
preparation, the final concentration of the solvent should not exceed 100 μL/L (0.01%). Because 
the solvent in this study was used in 10 times higher dose than OECD guidelines recommend 
we did an additional behavioural assay investigating if DMSO in the concentration of 0.1 % 
could cause changes in locomotor activity. Water without any additives were used as control.  
 
Table 1. Design of exposure in the different tests. Measurements of malformations and behaviour were 
performed at day 6 post fertilization (dpf). DMSO (0.1 %) were always included in both controls and 
all exposure groups. The groups exposed at day 6 were free from DMSO before exposure and 
exposure occurred one hour before start of behaviour recording 
Test 
 
Compound Concentration (mg/L) 
Normal test 
 
 Control Low (L) Medium (M) High (H) 
 Doramectin 0 0.058 0.18 0.58 
 Flumethrin 0 0.011 0.035 0.11 
 Toltrazuril 0 0.11 0.35 1.1 
      
Short 
exposure 
 
  
 Doramectin 0   0.58 
 
Embryo test and behaviour assay 
The embryos were placed in petri dishes with different concentrations of the pharmaceutical 
according to the exposure design (see table 1). Each embryo was then transferred, together with 
750 µl of the solution, to wells in 48-well plates. Each exposure group included 24 embryos. 
The plates were covered with parafilm and incubated for 6 days in a room with a consistent 
temperature of 26 ° C and a photoperiod of 12 h darkness and 12 h light. Embryos undergoing 
the short time exposure were placed in the wells together with 750µl of water and incubated 
under the same conditions as described above. At the morning day six, before the light was 
turned on in the room and 60 minutes prior to the locomotor assay, 7.5 µl of the different stock 
solutions were transferred to the wells.  
The larval behavioural assay was performed using the Viewpoint Zebrabox® behavioural 
recording device (ViewPointLife Sciences, Lyon, France). This equipment consists of a multi-
well plate holder (Zebrabox) in which a plate with zebrafish larvae can be placed. Inside the 
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Zebrabox is an automated camera system that records the activity of the larvae. The Zebrabox 
is equipped with internal LED lights and infrared illumination so recordings can be performed 
under light as well as dark conditions.  
On the day of recording, the light in the room was turned off. Hence, all zebrafish larvae were 
kept in entirely darkness until they were placed in the device and recorded.  Each 48-well plate 
was transferred to the Zebrabox where the larvae were allowed to acclimatize in light for 15 
minutes. After the acclimation phase, the locomotor activity was recorded in 18 consecutive 5-
min phases of alternate dark and light.  
Macroscopic evaluation of the larvae 
Directly after the behavioural assay all larvae were assessed in stereo microscope for 
abnormalities. Because the main purpose of this study was to test if a behavioural assay 
increases the sensitivity of the FET-test only individuals that was visual healthy (no anomalies, 
deformities or larvae that showed abnormal body posturing at rest) were included in the data 
set. Abnormal body posturing can be a sign of neuro toxicity. Dorso-ventral position (fig 1) was 
considered as the normal body position of a zebrafish larvae. The following abnormities in body 
posturing were found: side laying (fig 2a), tilting to one side (fig 2b), laying in a normal dorso-
ventral position but with lateral flexed back (fig 2c), tilting to one side with a lateral flexed back 
(fig 2d). The individuals that tilted to the side did this to various extent, from close to the normal 
dorso-ventral position to almost side laying. The ones that were close to dorso-ventral position 
often seemed to wobble and trying to correct themselves to a dorso-ventral position, but fell 
back into the tilted position immediately after they finished the attempt.  
 
 
Figure 1: The normal dorso-ventral body posturing of a zebrafish larvae. 
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2a             2b 
2c              2d 
Figure 2a-d. Abnormal body postures that was observed in the larvae: side laying (1a), tilting (1b), 
lateral flexed back (1c), tilting to one side with lateral flexed back (1d). 
 
Data analysis 
Individuals that did not met the previous mentioned criteria, visual healthy and no abnormal 
body posturing at rest, and dead individuals were excluded from the data set. The mean 
locomotor activity where then plotted as a function of time for each of the three 
pharmaceuticals. Based on these graphs four responses were chosen for statistical analysis: 
mean activity during the first period of darkness, mean activity during the first period of light, 
increase in activity during the first 10 seconds at the first period of darkness and difference 
between mean activity during the first and the last periods of darkness. These four responses 
were statistically analysed using ANOVA with Dunnett’s post-hoc test.  
RESULTS 
Visual inspection 
The result of the visual inspection of the embryos exposed to doramectin is presented in figure 
3a. The mortality rate was found to be 4.2 % in the control group (this represents one individual) 
and 8.3 % in the highest concentration. There was no mortality in the low and the medium 
concentrations. There were affected animals in all four groups including the control. The 
number of affected animals increased with the increasing concentration of doramectin, from 
12.5 % in the control group to 33.3 % in the highest concentration. Figure 3b shows the 
percentage of visually affected individuals in the flumethrin toxicity test. All 96 embryos were 
alive at day 6 so the overall mortality rate was 0 %. Figure 3b also shows that it was a quite 
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high number of affected animals in the control group (29.2 %). All of these were considered as 
affected based on abnormal body posturing. However, these individuals were considered as less 
severe affected than the affected individuals in the higher concentrations. All but one of the 
affected individuals in the control group showed tilting whereas the affected larvae in the 
highest concentration showed side laying and some had malformations. The total percentage of 
affected larvae in the highest concentration was 41.7 %. The percentage of affected larvae in 
the toltrazuril test is visualized in fig 3c. The number of affected animals were low in all three 
groups, ranging between 8.3-16.7 %. In the DMSO test the number of affected or dead larvae 
was approximately the same: 21 % for DMSO and 25 % for the control.  
Figure 3a-c. The percentage of dead and affected larvae in the different concentrations for the three 
tested pharmaceuticals.  
 
Behavioural assay 
The mean locomotor activity as a function of time for larvae treated with doramectin was 
plotted and can be seen in figure 4a. What is notable in the figure is that the highest 
concentration seems to have a consistent lower activity compared to the other groups. Figure 
4b shows the mean locomotor activity over time for larvae treated with flumethrin. 
Interestingly, the highest concentration seems to lack the initial peak, during the first seconds 
of darkness, which can be seen in the controls and in the other two concentrations. The overall 
activity in the highest concentration is strongly reduced over time while the activity of control 
and the other concentrations is approximately the same during the entire test period. The mean 
locomotor activity over time for treated larvae treated with toltrazuril can be seen in figure 4c. 
There were no obvious differences between the control and the different concentrations 
visualized in the graph. Figure 5 visualise the short exposure test with doramectin. Larvae that 
received doramectin 1h prior behavioural recording showed heavily reduced activity and almost 
none activity at all during the last 20 minutes of the recording. In the additional test with DMSO 
there were no differences in the graph between the larvae that received 0.01% DMSO and the 
control. 
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Figure 4. Locomotor activity means (mm per 10 s) in zebrafish larvae exposed to different veterinary 
pharmaceuticals in different concentrations: low (L), medium (M) and high (H) as well as controls (a-
c). The black line represents the control group and the coloured lines the different concentrations of 
the test substance: orange line for the low concentration, purple for the medium concentration and 
blue for the high concentration. The bars below each graph shows the five minute consecutive light 
and dark periods; white represents light and black represent darkness.  
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Figure 5.  Locomotor activity means (mm per 10 s) in zebrafish larvae that received doramectin 1h 
prior behavioural recording (D1h) as well as the corresponding control (C1h), the black line in the 
graph represents the control and the grey line represents the tested substance. The bars below each 
graph shows the five minute consecutive light and dark periods; white represents light and black 
represent darkness.  
 
Statistical analysis 
The result of the statistical analyses of the four selected responses revealed some effects in 
larval activity (table 2). The activity in the first five minutes dark period and the first five 
minutes light period were both significantly reduced in larvae exposed to the high concentration 
of doramectin compared with the control. Larvae exposed to the high concentration of 
flumethrin had a significant higher reduction in activity from the first to the last dark period as 
compared with the reduction in control larvae. The toltrazuril exposed larvae had no 
significantly difference in activity compared with the control group. In the control study of the 
impact of 0.1% DMSO on locomotor behaviour, the larvae that received 0.1 % DMSO did not 
differ from the controls. 
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Table 2. Results from the statistical analysis of the four selected responses in the behaviour test: 
increase in activity during the first 10 seconds at the first period of darkness (First 10 s of D1), mean 
activity during the first period of darkness (D1), mean activity during the first period of light (L1) and 
difference between mean activity during the first and the last periods of darkness (D9-D1)  
  mean distance (mm (±SD)) 
 
 
  Control (C) 
 
Low (L) 
 
Medium (M) 
 
High (H) 
 
P-value 
ANOVA 
Doramectin First 10 s of D1 12.91 
(14.33) 
14.56 
(20.41) 
11.85 
(17.38) 
22.14 
(17.59) 
0.870 
 D1 39.37 
(7.14) 
41.09 
(5.16) 
40.82 
(7.43) 
30.45 * 
(14.93) 
0.002 
 L1 26.66 
(9.42) 
23.17 
(10.90) 
24.57 
(9.79) 
16.25 * 
(14.49) 
0.043 
 D9-D1 -4.82 
(8.46) 
-2.04 
(12.24) 
-3.11 
(8.78) 
-0.99 
(19.13) 
0.806 
       
Flumethrin First 10 s of D1 6.61 (12.74) 11.87 
(16.77) 
8.86 (19.12) 2.20 (18.92) 0.443 
 D1 34.65 (7.23) 36.98 (6.80) 35.05 (10.49) 34.43 
(11.22) 
0.833 
 L1 22.08 (7.80) 20.83 
(10.01) 
22.93 (11.40) 19.92 
(11.46) 
0.843 
 D9-D1 0.18 (5.66) -2.45 (7.05) -2.45 (5.13) -10.60 ** 
(15.22) 
0.006 
       
Toltrazuril First 10 s of D1 9.50 (9.19) 12.48 
(16.64) 
18.25 (12.85) 14.49 
(13.14) 
0.171 
 D1 40.66 (7.69) 42.56 (6.36) 41.54 (7.84) 40.08 (8.46) 0.746 
 L1 25.43 (11.45) 27.11(10.95) 26.44 (10.46) 28.50 (7.38) 0.796 
 D9-D1 -1.11 (4.98) -1.66 (4.72) 0.25 (5.15) -2.25 (4.71) 0.389 
       
  mean distance (mm (±SD)) 
 
 
  Control (H2O) 
 
DMSO (0.1%) 
 
P - value 
DMSO First 10 s of D1 28.67 (22.70)  36.77 (18.66)  0.243 
 D1 42.35 (9.2)  42.7 (9.0)  0.392 
 L1 29.6 (13.4)  29.8 (13.1)  0.539 
 D9-D1 -8.0 (4.9)  -5.0 (5.3)  0.960 
Dunnett’s test: * = p ≤ 0.05 ** = p ≤ 0.01 
 
DISCUSSION 
Overview 
Because one aim of the present study was to test if adding a behavioural assay could increase 
the sensitivity of the fish embryo toxicity (FET) test, only larvae that had normal appearance 
and body posture at visual inspection were included in the data set. These criteria were set 
because if possibly toxic effects could be seen on forehand by visual inspection, a behavioural 
assay would not be necessary to make a statement about the toxicity of the substance. Three 
substances were tested in this study: doramectin, flumethrin and toltrazuril by using a 
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behavioural recording device that records the locomotor activity of the larvae. Because of the 
large amount of data produced, it was difficult to analyse all possible effects. Therefore, four 
measurements were chosen based of the graph of mean locomotor activity (fig. 4): mean activity 
during the first period of darkness, mean activity during the first period of light, increase in 
activity during the first 10 seconds at the first period of darkness and difference in mean activity 
between the first and the last period of darkness. These four measurements were tested 
statistically for differences between the control group and the different concentrations. 
Significant results were found for doramectin and flumethrin but not for toltrazuril. These 
behaviour effects were observed in relatively high concentrations which already have been 
determined as toxic corresponding to EC50 (Carlsson et al., 2013). However, the behavioural 
effects were observed in larvae which were considered as normal which implies that the activity 
recording may reveal effects not detected in the normal embryo toxicity test and that this gives 
additional information of the modes of action of the tested pharmaceuticals. This study 
successfully showed that it is possible to use behavioural measurements to increase sensitivity 
in the FET test which makes behavioural assays highly interesting for further development of 
the test. 
Doramectin 
Doramectin belongs to the avermectine family of veterinary drugs and its mechanism of action 
is that it binds to the glutamate-gated chloride (GluCl) receptor and GABA, which cause an 
increase in the membrane permeability, which leads to an influx of chloride ions into the cells 
(Martin, 1997). This leads to hyperpolarisation in motor neurons and muscle cells of nematodes 
and arthropods and thereby paralysis. GluCl receptors are only found in invertebrates, so fishes 
and mammals does not have these (Zemkova et al., 2014), this explains why the drug can affect 
the parasite but not the host. In this study we found significant results for two of the analysed 
behaviour parameters between the control and the highest concentration. The mean activity 
during the first periods in the high concentration were significantly reduced both in light and 
darkness. There was no significant difference in activity increase during the first 10 second or 
between first and last period of darkness compared with the controls.  
A second test was performed with doramectin to evaluate if the reduced activity seen in the first 
test was an effect of developmental changes or if it was a result of a direct neurotoxic effect on 
the nerve system of the larvae. This test showed that larvae exposed to doramectin one-hour 
prior reading were more severely affected than larvae that were continuously exposed from day 
0. This implies that the effects of doramectin is a result from a direct acting mechanism and not 
from developmental disturbances. It is reasonable to think that the effect that was seen in this 
test, were caused by the same mechanisms as in the target parasite. In the study by Carlsson et 
al. (2013) the exposure medium was tested for doramectin concentrations before the FET test 
were performed and at 144 hpf. The result suggested that there is a large reduction of doramectin 
concentration throughout the test period both due to embryo metabolism and abiotic 
breakdown. This implies that the embryos that were exposed one-hour prior to reading probably 
were exposed to a higher concentration during recording than the ones that were exposed from 
day 0. A study by Gellert & Heinrichsdorff (2001) investigated if susceptibility to chemical 
pollutants could be affected by the egg age. They found that eggs younger than 1h were more 
susceptible than older eggs and drew the conclusion that this was due to changing of 
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permeability of the chorion. In the present study the eggs were about 1-2.5 h old when exposed 
to the pharmaceuticals so the actual concentration that reached the embryos during the first two 
days may have been reduced. Another possible explanation is that the long term exposed 
embryos had time to adapt by upregulate important cell mechanisms such as the P-glycoprotein 
efflux pump. P glycoprotein is present in most organisms and mediate the transport of 
xenobiotics out of the cell. Fischer et al. (2013), showed that the abcb4 gene that encodes for a 
P-glycoprotein in zebrafishes is a major component of the multidrug resistance in zebrafish 
embryos. Long et al. (2011) exposed zebrafish embryos for heavy metals and analysed for 
transcriptional expression of another P-glycoprotein gene, abcb1. They found that toxic heavy 
metals stimulated the expression of the abcc1 gene in the embryos. Induction of the abcc1 
expression is a cell defensive mechanism.  
Flumethrin 
Flumethrin is a pyrethroid insecticide that acts on voltage-dependent sodium channels in nerves 
by slowing down the closing of the sodium activation gate (Valentine, 1990). This leads to 
delayed repolarisation of the nerve resulting in neural dysfunction in the parasites. For the 
highest concentration of flumethrin, a significant difference in mean locomotor activity 
between first and last period of darkness were found. The activity in the highest concentration 
of flumethrin decreased significantly more between the first and the last period of darkness 
compared to the control. A reduction in activity over the course of repeated dark cycles is 
considered normal. Ašmonaitė et al. (2016) also saw decrease in response after repeated cycles 
when they used behavioural assays to study the effect of silver ions and silver nanoparticles in 
zebrafish embryos. Their theory about the background of this change in response over time was 
that it could be an effect of habituation. Habituation is defined as “a behavioral response 
decrement that results from repeated stimulation and that does not involve sensory 
adaptation/sensory fatigue or motor fatigue” (Rankin et al., 2009). Wong et al. (2010) studied 
habituation in adult zebrafish and found that some substances, caffeine and pentylenetetrazole 
(an anxiogenic agent), impaired habituation. Ašmonaitė et al. (2016) also mentioned motor and 
sensory fatigue as an alternative explanation to the observed reduction of locomotor response. 
In the graph (fig 4b) the initial peak during the first 10 seconds of darkness seemed to be absent 
in the embryos exposed to the highest concentration of flumethrin. This effect was however not 
statistically significant. 
Toltrazuril 
Toltrazuril is a triazinonderivate that affects the perinuclear space, mitochondria, and the 
endoplasmatic reticulum of the parasites and leads to a reduction of enzymes in the respiratory 
chain (Harder & Haberkorn, 1989). It was included in this study because in the study by 
Carlsson et al. (2013) it reduced early spontaneous movements in the zebrafish embryos in a 
very high concentration. However, in the present study no behavioural effects of toltrazuril was 
found. The simplest explanation for this is that toltrazuril do not induce any behavioural 
changes, but an alternate explanation could be that the concentration used was too low. We used 
the concentration 1.1 mg/mL whereas in the study by Carlsson et al. (2013) toltrazuril showed 
an ”all-or-nothing” pattern; at 1.0 mg/mL there was a low percentage of affected embryos but 
at the nearest higher level of 2.2 mg/mL, almost all embryos were affected. The concentration 
used in the present study were chosen based on the calculated EC50 value from Carlsson et al 
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(2013) study, so it is possible that the concentration became slightly too low and therefore we 
could not see any effects at all.  
Behavioural assay as a tool to access toxicity  
We were able to detect altered behavioural response in individuals that had been treated with 
doramectin or flumethrin, and that were considered as normal according to the macroscopic 
examination. Therefore, we believe that behavioural assays have a great potential as a tool to 
increase the sensitivity in toxicological studies in zebrafish. An important part of this study was 
the fact that the individuals contributing to affected locomotory endpoints could not be 
classified as affected based on visual features. This excluded all individuals with malformations 
or other physical anomalies such as oedemas. Considering that two of the antiparasitic 
pharmaceuticals in the study have a neuro toxic mechanism of action in their target organisms 
we also decided to exclude all larvae that showed abnormal body posture, which can be 
interpreted as a sign of neuro toxicity. In this study we decided to have protocol with several 
cycles in order to be able to detect changes in activity over time. By using a protocol with many 
cycles and a longer total recording time (1.5 h) we were able to detect a change in response 
over time for flumethrin. The protocol is identical to the one used in a study by Ašmonaitė et 
al. (2016). 
Other comments 
The concentrations used in this study were selected based on the study by Carlsson et al. (2013) 
in which 15 veterinary pharmaceuticals were tested for toxicity in zebrafish embryos. The 
highest concentration in our study corresponds to the EC50-value determined in that study. 
According to the definition of EC50, 50% of the individuals would be affected at the given 
concentration. For doramectin 8.3 % died and 33.3 % were alive but affected in the 
concentration that responded to EC50 in the study by Carlsson et al. This gives a total of 41.6 % 
which can be considered as similar results. In the flumethrin test none of the embryos died but 
41.7 % were affected in the highest concentration which is also quite close to 50 %. For 
toltrazuril the percentage of affected larvae were low in all four groups. As earlier mentioned 
there is a possible explanation for this by the sudden shift in toxicity that could be seen in the 
study by Carlson et al (2013); from few affected to almost all affected when the substance 
reaches a certain concentration.  
The pharmaceuticals used in this study are fat soluble substances and therefore dissolves poorly 
in water. Therefore, we had to use a solvent, dimethyl sulfoxide (DMSO). The same solvent 
were used in the study by Carlsson et al. (2013) and in order to make both studies comparable, 
the same concentration of DMSO, 0.1% was used in the present study. The results from the 
comparisons between clean water and DMSO on zebrafish larval behaviour in the present study 
suggests that this concentration of DMSO does not affect the activity. 
CONCLUSIONS 
For two of the pharmaceuticals, doramectin and flumethrin, we were able to detect altered 
behavioural response in individuals that could not be classified as affected based on visual 
features. Therefore, we believe that behavioural assays have a great potential as a tool to 
increase the sensitivity in toxicological studies in zebrafish.  
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